

REFERENCES

- Ayuningtyas, et. al., 2014. Karakteristik Klinis Pasien Karsinoma Hepatoseluler: Studi Kasus di RSUP Dr Kariadi Semarang Periode 2010-2012.
- Bialecki, E.S., Di Bisceglie, A.M., 2005. Diagnosis of hepatocellular carcinoma. *HPB* 7, 26–34. <https://doi.org/10.1080/13651820410024049>
- Bosetti, C., Turati, F., La Vecchia, C., 2014. Hepatocellular carcinoma epidemiology. *Best Practice & Research Clinical Gastroenterology* 28, 753–770. <https://doi.org/10.1016/j.bpg.2014.08.007>
- Bruix, J., Reig, M., Sherman, M., 2016. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. *Gastroenterology* 150, 835–853. <https://doi.org/10.1053/j.gastro.2015.12.041>
- Cai, C., Zeng, J., Wu, H., Shi, R., Wei, M., Gao, Y., Ma, W., 2015. Association between hepatitis B virus infection and diabetes mellitus: A meta-analysis. *Experimental and Therapeutic Medicine* 10, 693–698. <https://doi.org/10.3892/etm.2015.2537>
- Carr, B.I., Guerra, V., 2017. Serum Albumin Levels in Relation to Tumor Parameters in Hepatocellular Carcinoma Patients. *The International Journal of Biological Markers* 32, 391–396. <https://doi.org/10.5301/ijbm.5000300>
- Chang, P.E., Ong, W.C., Lui, H.F., Tan, C.K., 2013. Epidemiology and Prognosis of Paraneoplastic Syndromes in Hepatocellular Carcinoma. *ISRN Oncology* 2013, 1–8. <https://doi.org/10.1155/2013/684026>
- Dhanasekaran, R., Bandoh, S., Roberts, L.R., 2016. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. *F1000Res* 5, 879. <https://doi.org/10.12688/f1000research.6946.1>
- Eastman, R.C., Carson, R.E., Orloff, D.G., Cochran, C.S., Perdue, J.F., Rechler, M.M., Lanau, F., Roberts, C.T., Shapiro, J., Roth, J., 1992. Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography. *J. Clin. Invest.* 89, 1958–1963. <https://doi.org/10.1172/JCI115803>
- Edge, S.B., Compton, C.C., 2010. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. *Ann Surg Oncol* 17, 1471–1474. <https://doi.org/10.1245/s10434-010-0985-4>
- El-Serag, H.B., Rudolph, K.L., 2007. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. *Gastroenterology* 132, 2557–2576. <https://doi.org/10.1053/j.gastro.2007.04.061>
- Ghouri, Y., Mian, I., Rowe, J., 2017. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. *J Carcinog* 16, 1. https://doi.org/10.4103/jcar.JCar_9_16
- Giannini, E.G., 2005. Liver enzyme alteration: a guide for clinicians. *Canadian Medical Association Journal* 172, 367–379. <https://doi.org/10.1503/cmaj.1040752>

- Gkamprela, E., 2017. Iron deficiency anemia in chronic liver disease: etiopathogenesis, diagnosis and treatment. *aog*.
<https://doi.org/10.20524/aog.2017.0152>
- Hamid, A.S., Tesfamariam, I.G., Zhang, Y., Zhang, Z.G., 2013. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. *Oncology Letters* 5, 1087–1092. <https://doi.org/10.3892/ol.2013.1169>
- Henry, Z.H., Caldwell, S.H., 2015. Obesity and Hepatocellular Carcinoma: A Complex Relationship. *Gastroenterology* 149, 18–20.
<https://doi.org/10.1053/j.gastro.2015.05.024>
- Janevska, D., Chaloska-Ivanova, V., Janevski, V., 2015. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. *Open Access Maced J Med Sci* 3, 732. <https://doi.org/10.3889/oamjms.2015.111>
- Kew, M.C., 2013. A toxins as a Cause of Hepatocellular Carcinoma. *J Gastrointestin Liver Dis* 22, 6.
- Kew, M.C., Santos, H.A.D., Sherlock, S., 1971. Diagnosis of Primary Cancer of the Liver. *BRITISH MEDICAL JOURNAL* 4.
- Kinoshita, A., 2015. Staging systems for hepatocellular carcinoma: Current status and future perspectives. *WJH* 7, 406.
<https://doi.org/10.4254/wjh.v7.i3.406>
- Kitai, S., Kudo, M., Izumi, N., Kaneko, S., Ku, Y., Kokudo, N., Sakamoto, M., Takayama, T., Nakashima, O., Kadoya, M., Matsuyama, Y., Matsunaga, T., for the Liver Cancer Study Group of Japan, 2014. Validation of Three Staging Systems for Hepatocellular Carcinoma (JIS Score, Biomarker-Combined JIS Score and BCLC System) in 4,649 Cases from a Japanese Nationwide Survey. *Dig Dis* 32, 717–724.
<https://doi.org/10.1159/000368008>
- Leung, C., 2015. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. *WJG* 21, 1189.
<https://doi.org/10.3748/wjg.v21.i4.1189>
- Leung, T.W.T., Tang, A.M.Y., Zee, B., Lau, W.Y., Lai, P.B.S., Leung, K.L., Lau, J.T.F., Yu, S.C.H., Johnson, P.J., 2002. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. *Cancer* 94, 1760–1769. <https://doi.org/10.1002/cncr.10384>
- Levy, I., 2002. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. *Gut* 50, 881–885. <https://doi.org/10.1136/gut.50.6.881>
- Marrero, J.A., Kulik, L.M., Sirlin, C.B., Zhu, A.X., Finn, R.S., Abecassis, M.M., Roberts, L.R., Heimbach, J.K., 2018. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. *Hepatology* 68, 723–750. <https://doi.org/10.1002/hep.29913>

- McGlynn, K.A., Petrick, J.L., London, W.T., 2015. Global Epidemiology of Hepatocellular Carcinoma. *Clinics in Liver Disease* 19, 223–238. <https://doi.org/10.1016/j.cld.2015.01.001>
- Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J.M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y.K., Shiina, S., Jafri, W., Payawal, D.A., Ohki, T., Ogasawara, S., Chen, P.-J., Lesmana, C.R.A., Lesmana, L.A., Gani, R.A., Obi, S., Dokmeci, A.K., Sarin, S.K., 2017. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 11, 317–370. <https://doi.org/10.1007/s12072-017-9799-9>
- Ramadori, P., Klag, T., Malek, N.P., Heikenwalder, M., 2019. Platelets in chronic liver disease, from bench to bedside. *JHEP Reports* 1, 448–459. <https://doi.org/10.1016/j.jhepr.2019.10.001>
- Sakisaka, S., Watanabe, M., Tateishi, H., Harada, M., Shakado, S., Mimura, Y., Gondo, K., Yoshitake, M., Noguchi, K., Hino, T., Nohno, R., Majima, Y., Hirai, K., Sata, M., Yoshida, H., Tanikawa, K., 1993. Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: Immunohistochemical evidence. *Hepatology* 18, 1357–1362. <https://doi.org/10.1002/hep.1840180612>
- Sanyal, A.J., Yoon, S.K., Lencioni, R., 2010. The Etiology of Hepatocellular Carcinoma and Consequences for Treatment. *The Oncologist* 15, 14–22. <https://doi.org/10.1634/theoncologist.2010-S4-14>
- Shebl, F.M., Capo-Ramos, D.E., Graubard, B.I., McGlynn, K.A., Altekruse, S.F., 2012. Socioeconomic Status and Hepatocellular Carcinoma in the United States. *Cancer Epidemiology Biomarkers & Prevention* 21, 1330–1335. <https://doi.org/10.1158/1055-9965.EPI-12-0124>
- Testino, G., Leone, S., Borro, P., 2014. Alcohol and hepatocellular carcinoma: A review and a point of view. *WJG* 20, 15943. <https://doi.org/10.3748/wjg.v20.i43.15943>
- Wahyuningtyas, D. 2016. Profil Pasien Karsinoma Hepatoseluler di RSUP Dr Sardjito Yogyakarta.
- Wang, Y., Lau, S.H., Sham, J.S.-T., Wu, M.-C., Wang, T., Guan, X.-Y., 2004. Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis. *Oncogene* 23, 142–148. <https://doi.org/10.1038/sj.onc.1206889>
- Welzel, T.M., Graubard, B.I., Quraishi, S., Zeuzem, S., Davila, J.A., El-Serag, H.B., McGlynn, K.A., 2013. Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States: American Journal of Gastroenterology 108, 1314–1321. <https://doi.org/10.1038/ajg.2013.160>
- Xue, T., Ge, N., Xu, X., Le, F., Zhang, B. and Wang, Y., 2016. High platelet counts increase metastatic risk in huge hepatocellular carcinoma undergoing transarterial chemoembolization. *Hepatology Research*, 46(10), pp.1028-1036.
- Yau, T., Yao, T.J., Chan, P., Ng, K., Fan, S.T., Poon, R.T.P., 2008. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: Implication for patient

selection in systemic therapy trials. *Cancer* 113, 2742–2751.

<https://doi.org/10.1002/cncr.23878>

Zamor, P.J., deLemos, A.S., Russo, M.W., 2017. Viral hepatitis and hepatocellular carcinoma: etiology and management. *J. Gastrointest. Oncol.* 8, 229–242. <https://doi.org/10.21037/jgo.2017.03.14>